Levosimendan Tillomed

Levosimendan, the active ingredient in Levosimendan Tillomed, is a calcium sensitizer presented as a intravenous solution for intravenous use. It treats acute decompensated heart failure and cardiogenic shock in hospitalized adults.

GNH USA supplies Levosimendan Tillomed as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Levosimendan is an inotropic agent used in severe cardiac conditions where contractility is compromised. - Acute decompensated heart failure: improves cardiac output and relieves congestion. - Cardiogenic shock: stabilises haemodynamics and supports organ perfusion. - Advanced chronic heart failure (intermittent infusion): provides temporary haemodynamic support during worsening episodes.

Levosimendan may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea: occasional gastrointestinal upset. - Tachycardia: increase in heart rate. - Arrhythmias: non‑sustained ventricular ectopy. - Flushing: transient skin reddening.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Ventricular tachycardia or fibrillation: life‑threatening rhythm disturbances. - Myocardial ischaemia: chest pain or ECG changes. - Anaphylactic reaction: rare but possible hypersensitivity. - Pulmonary oedema worsening: in patients with fluid overload. - Liver enzyme elevation: transient hepatic dysfunction.

Levosimendan requires careful monitoring and specific safety measures before and during therapy. - Blood pressure monitoring: watch for hypotension and adjust infusion rate. - Cardiac rhythm surveillance: detect arrhythmias early. - Dose adjustment: consider renal or hepatic impairment when setting infusion parameters. - Contraindication in severe hypotension: avoid use when systolic BP is <90 mmHg. - Caution with mechanical obstruction: do not use in patients with outflow tract obstruction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent vasodilators (e.g., nitroglycerin): may cause profound hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase levosimendan plasma concentrations. - Other inotropes (e.g., dobutamine): additive risk of arrhythmias.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the positive inotropic effect. - Diuretics: can exacerbate volume depletion and hypotension. - ACE inhibitors or ARBs: may enhance hypotensive response.